drugset / Trial / NCT06793956
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).
Timeline
- Start
- 2025-02-21
- Primary completion
- 2026-01-31
- Completion
- 2030-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | — | Oral |
| Subject | Sintilimab | Monoclonal antibody | — | Intravenous |